|
Purdue’s Pediatric OxyContin Trial to Update Label Would Snag Six-Month Patent Extension
Purdue Pharma is denying reports it plans to seek FDA approval for pediatric OxyContin, despite an ongoing clinical trial studying the painkiller in children ages six to 16.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives